Heron Neutron Medical Corp.
Heron Neutron Medical Corp. develops, manufactures, and sells medical instruments. It offers accelerator-based boron neutron capture therapy solutions, including neutron source target system, accelerator system, target system, beam shaping assembly, treatment control system, treatment planning system, and patient positioning system; and ACSI cyclotron products. The company was founded in 2017 and… Read more
Heron Neutron Medical Corp. (7799) - Net Assets
Latest net assets as of June 2025: NT$1.33 Billion TWD
Based on the latest financial reports, Heron Neutron Medical Corp. (7799) has net assets worth NT$1.33 Billion TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.39 Billion) and total liabilities (NT$55.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.33 Billion |
| % of Total Assets | 96.02% |
| Annual Growth Rate | 43.84% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 26.69 |
Heron Neutron Medical Corp. - Net Assets Trend (2021–2024)
This chart illustrates how Heron Neutron Medical Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Heron Neutron Medical Corp. (2021–2024)
The table below shows the annual net assets of Heron Neutron Medical Corp. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.47 Billion | +82.59% |
| 2023-12-31 | NT$806.40 Million | +36.57% |
| 2022-12-31 | NT$590.48 Million | +19.37% |
| 2021-12-31 | NT$494.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Heron Neutron Medical Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 47264700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$2.07 Billion | 140.48% |
| Total Equity | NT$1.47 Billion | 100.00% |
Heron Neutron Medical Corp. Competitors by Market Cap
The table below lists competitors of Heron Neutron Medical Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Godfrey Phillips India Limited
NSE:GODFRYPHLP
|
$1.05 Billion |
|
SolarWinds Corp
NYSE:SWI
|
$1.05 Billion |
|
Tata Technologies Limited
NSE:TATATECH
|
$1.05 Billion |
|
MIRAIT ONE Corporation
PINK:MRHLF
|
$1.05 Billion |
|
TKH Group NV
AS:TWEKA
|
$1.05 Billion |
|
Dorian LPG Ltd
NYSE:LPG
|
$1.05 Billion |
|
Air Transport Services Group Inc
NASDAQ:ATSG
|
$1.05 Billion |
|
Ternium Argentina SA
BA:TXAR
|
$1.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Heron Neutron Medical Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 806,403,000 to 1,472,423,000, a change of 666,020,000 (82.6%).
- Net loss of 260,077,000 reduced equity.
- New share issuances of 903,550,000 increased equity.
- Other factors increased equity by 22,547,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-260.08 Million | -17.66% |
| Share Issuances | NT$903.55 Million | +61.36% |
| Other Changes | NT$22.55 Million | +1.53% |
| Total Change | NT$- | 82.59% |
Book Value vs Market Value Analysis
This analysis compares Heron Neutron Medical Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 40.13x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 119.46x to 40.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$3.52 | NT$420.00 | x |
| 2022-12-31 | NT$4.20 | NT$420.00 | x |
| 2023-12-31 | NT$5.73 | NT$420.00 | x |
| 2024-12-31 | NT$10.47 | NT$420.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Heron Neutron Medical Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.66%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-17.66%) is below the historical average (-15.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -14.60% | 0.00% | 0.00x | 1.07x | NT$-145.23 Million |
| 2023 | -15.67% | -53105.04% | 0.00x | 1.04x | NT$-207.03 Million |
| 2024 | -17.66% | 0.00% | 0.00x | 1.05x | NT$-407.32 Million |
Industry Comparison
This section compares Heron Neutron Medical Corp.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,274,214,400
- Average return on equity (ROE) among peers: 6.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Heron Neutron Medical Corp. (7799) | NT$1.33 Billion | -14.60% | 0.04x | $1.05 Billion |
| Health & Life Co., Ltd. (1781) | $372.58 Million | -4.71% | 1.15x | $12.97 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.65 Million |
| Wellell Inc (4106) | $1.31 Billion | 13.81% | 0.24x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.33 Billion | 1.93% | 1.30x | $38.32 Million |
| United Orthopedic (4129) | $1.77 Billion | 7.55% | 0.46x | $300.33 Million |
| Dynamic Medical Technologies (4138) | $1.76 Billion | 11.67% | 0.71x | $39.41 Million |
| Ok Biotech Co Ltd (4155) | $1.30 Billion | 9.66% | 0.71x | $44.61 Million |
| Bioptik Technology (4161) | $717.83 Million | 6.76% | 1.11x | $30.42 Million |
| EPS Bio Technology Corp. (4183) | $309.15 Million | 10.25% | 0.77x | $4.27 Million |